| Patient | Barbara Jordan |
|---|---|
| Date of birth | 1936-02-21 |
| Identifiers | MRN HR-ML030-SYN-TD; SSN (made up) 000-30-6852 |
| Document date | 1980-10-26 |
| Author | Evangeline Moss, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Eight-month review before the first full ocrelizumab dose: re-baseline brain MRI, blood counts and immunoglobulins, seasonal vaccines, mobility and work. [S]
Ms. Jordan returns ten weeks after her preventive visit, with a re-baseline brain MRI this morning. She has had no new symptoms and no infection since her first doses. Her mammogram in August was normal, and her HPV test was negative. The heat sensitivity eased as the weather cooled. She finished her course of physical therapy and keeps up her home program and pool exercise; she has had no falls since the near-fall in July. She is teaching a full term and gave two public lectures this month, seated at a lectern. She gets up once a night or less. Dr. Watanabe has reviewed the MRI. Her next infusion, the first full 600 mg dose, is booked in two weeks. [S]
| Element | Detail |
|---|---|
| New symptoms | None |
| Screening | Mammogram normal; HPV negative |
| Falls | None; one near-fall in July |
| Work | Full teaching term and public lectures |
| Next infusion | 600 mg in two weeks |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever, infection or weight change |
| Respiratory | Negative | No cough |
| Gastrointestinal | Negative | No diarrhea |
| Genitourinary | Negative | No burning; nocturia once or less |
| Neurological | Negative | No new numbness, weakness or visual change |
| Psychiatric | Negative | Mood steady |
6 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Cholecalciferol (vitamin D3) 1954 units (50 mcg) oral capsule, one capsule daily | One capsule daily | Oral route | 1980-03-02 | active | S |
| Baclofen 5 mg oral tablet, one tablet three times a day, to be increased to 10 mg three times a day once tolerated | One tablet three times a day | Oral route | 1980-03-16 to 1980-04-20 | completed | S |
| Baclofen 10 mg oral tablet, one tablet three times a day | One tablet three times a day | Oral route | 1980-04-20 | active | S |
| Mirabegron 25 mg extended-release oral tablet, one tablet daily | One tablet daily | Oral route | 1980-03-16 | active | S |
| Ocrelizumab 300 mg intravenous infusion on day 1 and day 15, then 600 mg every 6 months, after methylprednisolone 100 mg intravenously, an antihistamine and acetaminophen, in the infusion center | 300 mg on day 1 and day 15 (given), then 600 mg every 6 months | Intravenous route | 1980-05-04 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1980-10-26 | Body height | 173 | cm | S |
| 1980-10-26 | Body weight | 83.2 | kg | S |
| 1980-10-26 | Body mass index (BMI) [Ratio] | 27.8 | kg/m2 | S |
| 1980-10-26 | Systolic blood pressure | 120 | mm[Hg] | S |
| 1980-10-26 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 1980-10-26 | Heart rate | 72 | /min | S |
| 1980-10-26 | Respiratory rate | 16 | /min | S |
| 1980-10-26 | Body temperature | 36.6 | Cel | S |
| 1980-10-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1980-10-26 | Leukocytes [#/volume] in Blood by Automated count | 6.1 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1980-10-26 | Lymphocytes [#/volume] in Blood by Automated count | 1.5 | 10*3/uL | 1-4.8 10*3/uL | Normal | S |
| 1980-10-26 | Hemoglobin [Mass/volume] in Blood | 13.5 | g/dL | 12-15.5 g/dL | Normal | S |
| 1980-10-26 | Platelets [#/volume] in Blood by Automated count | 255 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1980-10-26 | IgG [Mass/volume] in Serum or Plasma | 1010 | mg/dL | 700-1600 mg/dL | Normal | S |
| 1980-10-26 | IgM [Mass/volume] in Serum or Plasma | 72 | mg/dL | 40-230 mg/dL | Normal | S |
| 1980-10-26 | Creatinine [Mass/volume] in Serum or Plasma | 0.8 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 1980-10-26 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1975)/1.73 sq M | 93 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1980-10-26 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 19 | U/L | 7-35 U/L | Normal | S |
| 1980-10-26 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 21 | U/L | 10-35 U/L | Normal | S |
Vital signs recorded on 1980-10-26; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 83.2 kg; blood pressure 120/76, pulse 72; temperature 36.6 °C |
| Neurological | Spastic gait with a cane; modified Ashworth 1+ in both legs; hip flexor strength 4 out of 5; EDSS 6.0; timed 25-foot walk 11.0 seconds |
| Skin | No rash or cold sores |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Multiple sclerosis diagnosed elsewhere, by her account, with records of the original evaluation not available: slowly worsening walking over the past few years, leg stiffness, fatigue, urinary urgency and heat sensitivity; uses a cane; course to be classified after MRI of the brain and spine | resolved | confirmed | G35.D | S — Synthetic presenting picture at intake, superseded by the classified diagnosis at the consultation; the cane and a diagnosis around the time she left Congress are from public accounts. |
| Active primary progressive multiple sclerosis: gradual worsening of walking over more than a year without relapses, with brain lesions in periventricular, juxtacortical and infratentorial regions, three spinal cord lesions, and one gadolinium-enhancing lesion; fulfils the 1971 McDonald criteria for primary progressive disease; EDSS 6.0; synthetic modern detail linked to her publicly reported multiple sclerosis | active | confirmed | G35.B1 | S — Synthetic course, MRI findings and disability score; the disease itself and her use of a cane are from public accounts. |
| Spastic gait from multiple sclerosis, walking with a cane, with two near-falls and no falls in the past year; at risk of falls | active | confirmed | R26.89 | S — Synthetic modern coding anchored to her documented cane. |
| Neurogenic bladder from multiple sclerosis: urgency and getting up twice at night, with a low post-void residual | active | confirmed | N31.9 | S — Synthetic; common in multiple sclerosis. No public source describes her bladder. |
| Vitamin D deficiency | active | confirmed | E55.9 | S — Synthetic laboratory finding at intake. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | New or worsening symptoms (relapse, pseudo-relapse with heat or infection) | Every visit | Completed today | No relapse in eight months |
| Examination | Disability: EDSS and timed 25-foot walk | Every visit, and at least every 6 months | Completed today | EDSS 6.0; timed 25-foot walk 11.0 seconds |
| Imaging | Brain MRI | At diagnosis with gadolinium; re-baseline 3 to 6 months after starting therapy; then yearly without routine gadolinium | Completed today | Re-baseline without gadolinium, five to six months after the first dose: no new or enlarging T2 lesions; next in one year |
| Imaging | Spinal cord MRI | At diagnosis; later only for new spinal symptoms or diagnostic doubt | Not indicated | No new spinal symptoms |
| Laboratory | Blood count with absolute lymphocytes | Before the first dose, then before each dose | Completed today | White cells 6.1, lymphocytes 1.5, hemoglobin 13.5, platelets 255 |
| Laboratory | Quantitative immunoglobulins | Before the first dose, then before each dose | Completed today | IgG 1010, IgM 72 mg/dL |
| Laboratory | Liver tests | Before the first dose, then with symptoms and before each dose | Completed today | ALT 19, AST 21 U/L; creatinine 0.80 mg/dL |
| Medication safety | Infusion reactions and infections | Each infusion, and every visit | Completed today | No infections; 600 mg dose booked in two weeks |
| Medication safety | Influenza and COVID-19 vaccines | Each season, ideally at least 2 weeks before an infusion | Completed today | Both given today |
| Medication safety | Breast cancer screening (ocrelizumab label: standard screening) | Every two years from 40 | Up to date | Mammogram normal in August |
| Examination | Spasticity (modified Ashworth) and baclofen tolerance | Every visit | Completed today | Modified Ashworth 1+ |
| Examination | Bladder: urgency, nocturia, urinary infection, and blood pressure on mirabegron | Every visit | Completed today | Nocturia once or less; blood pressure 120/76 |
| Referral | Falls, walking aids and physical therapy | Every visit | Completed today | Physical therapy course completed; no falls |
| Self-management | Fatigue and heat sensitivity | Every visit | Completed today | Heat sensitivity eased with cooler weather |
| Laboratory | 25-hydroxyvitamin D | At baseline, 8 to 12 weeks after repletion, then yearly | Up to date | 34 ng/mL four months ago; recheck at one year |
| Imaging | Bone density | Once for reduced mobility and earlier steroid courses; repeat by risk | Up to date | Normal for age at the preventive visit |
| Survey | Depression screen (PHQ-9) | At intake, then every 6 months and with any change | Due | PHQ-9 3 four months ago and PHQ-2 0 ten weeks ago; next PHQ-9 at the next review |
| Self-management | Workplace accommodation | At intake and with any change | Completed today | Accommodations working; no change needed |
| Referral | Multiple sclerosis neurology review | At diagnosis, then every 6 months on therapy | Completed today | Dr. Watanabe reviewed the MRI and results and agreed with the plan; review in six months |
Goal progress:
Immunizations given today: Influenza vaccine, inactivated, this season; COVID-19 vaccine, mRNA, this season [S]
Guideline basis: Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis (Rae-Grant A, et al.; PMID 29686116) (2018); 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis (Wattjes MP, et al.; PMID 34139157) (2021); Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis (Farez MF, et al.; PMID 31462584) (2019); OCREVUS (ocrelizumab) injection, prescribing information (2026); Multiple sclerosis in adults: management (NG220) (2022); Accommodation and Compliance: Multiple Sclerosis (2026); Introduction to the Americans with Disabilities Act (2026); Adult Immunization Schedule by Age (2026); Depression and Suicide Risk in Adults: Screening (2023); CMID: Clinical Monitoring Intelligence Database, osteoporosis and depression monographs (2026); Breast Cancer: Screening (2024)
Follow-up: Ocrelizumab 600 mg in two weeks. Review in three months with the PHQ-9, or the same day for new or worsening symptoms lasting more than 24 hours, fever, or a persistent infection. [S]